159 related articles for article (PubMed ID: 24443788)
1. High prevalence of Y-box protein-1/p18 fragment in plasma of patients with malignancies of different origin.
Tacke F; Galm O; Kanig N; Yagmur E; Brandt S; Lindquist JA; Eberhardt CS; Raffetseder U; Mertens PR
BMC Cancer; 2014 Jan; 14():33. PubMed ID: 24443788
[TBL] [Abstract][Full Text] [Related]
2. Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease.
Tacke F; Kanig N; En-Nia A; Kaehne T; Eberhardt CS; Shpacovitch V; Trautwein C; Mertens PR
BMC Cancer; 2011 May; 11():185. PubMed ID: 21595987
[TBL] [Abstract][Full Text] [Related]
3. Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).
Rohr I; Braicu EI; En-Nia A; Heinrich M; Richter R; Chekerov R; Dechend R; Heidecke H; Dragun D; Schäfer R; Gorny X; Lindquist JA; Brandt S; Sehouli J; Mertens PR
Cytokine; 2016 Sep; 85():157-64. PubMed ID: 27371774
[TBL] [Abstract][Full Text] [Related]
4. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.
Dahl E; En-Nia A; Wiesmann F; Krings R; Djudjaj S; Breuer E; Fuchs T; Wild PJ; Hartmann A; Dunn SE; Mertens PR
BMC Cancer; 2009 Nov; 9():410. PubMed ID: 19930682
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
6. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M
J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825
[TBL] [Abstract][Full Text] [Related]
7. Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer.
Gessner C; Woischwill C; Schumacher A; Liebers U; Kuhn H; Stiehl P; Jürchott K; Royer HD; Witt C; Wolff G
Eur Respir J; 2004 Jan; 23(1):14-9. PubMed ID: 14738225
[TBL] [Abstract][Full Text] [Related]
8. High expression of Y-box-binding protein 1 is associated with local recurrence and predicts poor outcome in patients with colorectal cancer.
Yan X; Yan L; Zhou J; Liu S; Shan Z; Jiang C; Tian Y; Jin Z
Int J Clin Exp Pathol; 2014; 7(12):8715-23. PubMed ID: 25674237
[TBL] [Abstract][Full Text] [Related]
9. Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site.
Molina R; Bosch X; Auge JM; Filella X; Escudero JM; Molina V; Solé M; López-Soto A
Tumour Biol; 2012 Apr; 33(2):463-74. PubMed ID: 22161237
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and prognostic significance of tumor markers cytokeratin 19 fragment, carcinoembryonic antigen, and neuron-specific enolase in lung cancer].
Zemaitis M; Sakalauskas R; Malakauskas K; Muley T; Fischer JR; Lahm H
Medicina (Kaunas); 2005; 41(7):566-76. PubMed ID: 16062024
[TBL] [Abstract][Full Text] [Related]
11. Expression of Y-box-binding protein YB-1 allows stratification into long- and short-term survivors of head and neck cancer patients.
Kolk A; Jubitz N; Mengele K; Mantwill K; Bissinger O; Schmitt M; Kremer M; Holm PS
Br J Cancer; 2011 Dec; 105(12):1864-73. PubMed ID: 22095225
[TBL] [Abstract][Full Text] [Related]
12. The Role of Serum Tumor Markers in Follow-up After Surgical Treatment of Malignant Lung Tumors.
Vodicka J; Skala M; Sebek J; Treska V; Fichtl J; Prochazkova K; Vankova B; Svaton M; Pecen L; Topolcan O; Bludovska M; Kucera R
Anticancer Res; 2021 Oct; 41(10):5117-5122. PubMed ID: 34593462
[TBL] [Abstract][Full Text] [Related]
13. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
[TBL] [Abstract][Full Text] [Related]
14. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
[TBL] [Abstract][Full Text] [Related]
15. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.
Molina R; Marrades RM; Augé JM; Escudero JM; Viñolas N; Reguart N; Ramirez J; Filella X; Molins L; Agustí A
Am J Respir Crit Care Med; 2016 Feb; 193(4):427-37. PubMed ID: 26465739
[TBL] [Abstract][Full Text] [Related]
16. YB-1, the E2F pathway, and regulation of tumor cell growth.
Lasham A; Samuel W; Cao H; Patel R; Mehta R; Stern JL; Reid G; Woolley AG; Miller LD; Black MA; Shelling AN; Print CG; Braithwaite AW
J Natl Cancer Inst; 2012 Jan; 104(2):133-46. PubMed ID: 22205655
[TBL] [Abstract][Full Text] [Related]
17. [Significance of serum tumor markers monitoring metastases in carcinomas of unknown primary site].
Pejcić I; Vrbić S; Filipović S; Sćekić M; Petković I; Pejcić L; Djenić N
Vojnosanit Pregl; 2010 Sep; 67(9):723-31. PubMed ID: 20954411
[TBL] [Abstract][Full Text] [Related]
18. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen.
Niho S; Nishiwaki Y; Goto K; Ohmatsu H; Matsumoto T; Hojo F; Ohe Y; Kakinuma R; Kodama T
Lung Cancer; 2000 Mar; 27(3):159-67. PubMed ID: 10699689
[TBL] [Abstract][Full Text] [Related]
19. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
[TBL] [Abstract][Full Text] [Related]
20. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer.
Yoshimatsu T; Uramoto H; Oyama T; Yashima Y; Gu C; Morita M; Sugio K; Kohno K; Yasumoto K
Anticancer Res; 2005; 25(5):3437-43. PubMed ID: 16101161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
